MHRA Alert – IXCHIQ Chikungunya vaccine: age restrictions updated following safety review

IXCHIQ Chikungunya vaccine: updated use restrictions

The MHRA has completed a safety review of IXCHIQ (chikungunya vaccine) and, following recommendations from the Commission on Human Medicines (CHM), important changes to its licensed indications have been made.

Key points

• IXCHIQ is no longer indicated for adults over 60 years of age
• The vaccine is now contraindicated in this age group
• These restrictions follow a formal safety review and CHM recommendation
• Healthcare providers and clinicians should review their vaccination protocols accordingly

Affected medication

• IXCHIQ (chikungunya vaccine)

What you should do

If you are involved in chikungunya vaccination programmes or advise patients on travel health:

• Check the updated product information and contraindications
• Do not offer IXCHIQ to patients aged 60 years and over
• Consider alternative preventive measures for older travellers to chikungunya-endemic regions
• Update your local protocols and patient information materials

For the full regulatory statement and detailed safety information, visit the MHRA drug safety update.